Dossier assessment
Ribociclib (breast cancer; combination with aromatase inhibitors) - Benefit assessment according to §35a Social Code Book V
Report documents
-
Extract of dossier assessment
Ribociclib (breast cancer; combination with aromatase inhibitors) - Benefit assessment according to §35a Social Code Book V
-
Dossier assessment
Ribociclib (breast cancer; combination with aromatase inhibitors) - Benefit assessment according to §35a Social Code Book V
Press releases
Ribociclib in breast cancer: added benefit for certain women after menopause
Additional information
Federal Joint Committee (G-BA)
2020-08-20: G-BA decision was published.
Project details
- Project no.
- A20-21
- Commission
- Commission awarded on 02.03.2020 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Cancer
- Note
-
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
Connected Projects
-
Dossier assessment
Ribociclib (breast cancer; combination with fulvestrant) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Ribociclib (breast cancer) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Ribociclib (breast cancer) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Addendum
Ribociclib (breast cancer, combination with an aromatase inhibitor) - Addendum to commission A20-21
Status: Commission completed
-
Dossier assessment
Ribociclib (breast cancer, adjuvant treatment) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed